Artiva Biotherapeutics earnings release, May 8, 2026

Artiva Biotherapeutics, Inc. (ARTV) · Form 8-K, Item 2.02 · Filed · SEC filing

Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Initial AlloNK®

(AB-101) clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no patients relapsing or requiring new immunomodulatory agents

AlloNK treatment regimen demonstrated a consistent pattern of deep

B-cell depletion and tolerability results supportive of outpatient administration in community rheumatology settings

U.S. Food and Drug Administration (FDA) alignment on a single Phase 3 registrational randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 refractory

RA patients, with ACR50 at six months as the primary endpoint; trial initiation planned for H2 2026

Multiple oral and poster presentations at EULAR 2026, including a late-breaking oral presentation on

AlloNK clinical efficacy in refractory RA, Sjögren disease (SjD) and systemic sclerosis (SSc)

SAN DIEGO, May 8, 2026 — Artiva Biotherapeutics, Inc.

(Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced financial results for the first quarter ended March 31, 2026, and highlighted recent progress.

“Artiva has reached an important inflection point, with positive initial clinical data across multiple autoimmune diseases and FDA alignment on a single

Phase 3 registrational trial design in refractory RA,” said Fred Aslan, M.D., president and chief executive officer of Artiva Biotherapeutics. “The initial RA data demonstrated meaningful responses in highly refractory patients, alongside a tolerability profile supportive of outpatient administration in community rheumatology settings. Together, these data support AlloNK’s potential to become the first deep

B-cell depleting therapy to advance into a Phase 3 trial in refractory RA, the autoimmune indication with the largest number of refractory patients.”

Dr. Aslan continued, “By combining deep B-cell depletion, meaningful clinical responses and an outpatient profile suited to community rheumatology practices, AlloNK has the potential to redefine the treatment paradigm for patients with refractory autoimmune disease.”

Recent Business Highlights

Reported positive initial clinical data from ongoing clinical trials evaluating AlloNK in combination with rituximab across multiple autoimmune diseases

Achieved FDA alignment on Phase 3 registrational trial design in refractory RA

Upcoming Milestones

Present AlloNK clinical data at

EULAR 2026

Initiate Phase 3 registrational trial in refractory RA

First Quarter 2026 Financial Results

About Artiva Biotherapeutics

Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases. Artiva’s lead program, AlloNK®

(also known as

AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive

B-cell depletion. AlloNK is currently being evaluated in three ongoing clinical trials for the treatment of

B-cell driven autoimmune diseases, including a company-sponsored basket trial across autoimmune diseases that includes rheumatoid arthritis and Sjögren’s disease and an investigator-initiated basket trial in

B-cell driven autoimmune diseases. Artiva plans to initiate a Phase 3 registrational trial evaluating AlloNK in refractory RA in 2026. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to

GC Cell’s NK cell manufacturing technology and programs.

Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.

Financial statements

Income Statement

Three Months Ended March 31, — (in thousands, except share and per share data)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Operating expenses:Research and development19,31217,052
Operating expenses:General and administrative5,1185,119
Operating expenses:Total operating expenses24,43022,171
Operating expenses:Loss from operations-24,430-22,171
Other income, net:Interest income9121,864
Other income, net:Other income (expense), net2-4
Other income, net:Total other income, net9141,860
Other income, net:Net loss-23,516-20,311
Other income, net:Net loss per share, basic and diluted-0.95-0.83
Other income, net:Weighted-average common shares outstanding, basic and diluted24,678,42024,341,978
Comprehensive loss:Net loss-23,516-20,311
Comprehensive loss:Other comprehensive (loss) income, net-121129
Comprehensive loss:Comprehensive loss-23,637-20,182

Balance Sheet

March 31, 2026 — (in thousands)

March 31, 2026December 31, 2025
AssetsCash, cash equivalents and investments86,782108,008
AssetsProperty and equipment, net6,2166,618
AssetsOperating and financing lease right-of-use assets10,08010,737
AssetsOther assets2,8775,577
AssetsTotal assets105,955130,940
Liabilities and stockholders’ equityAccounts payable and accrued expenses7,8459,955
Liabilities and stockholders’ equityOperating and financing lease liabilities10,26310,942
Liabilities and stockholders’ equityOther liabilities73
Liabilities and stockholders’ equityTotal liabilities18,10820,970
Liabilities and stockholders’ equityStockholders’ equity87,847109,970
Liabilities and stockholders’ equityTotal liabilities and stockholders’ equity105,955130,940
Full release

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: expectations of Artiva regarding the potential benefits, accessibility, effectiveness and safety of AlloNK®, including based on interim pooled data across clinical trials; Artiva’s registrational strategy, including trial design, plans to conduct a single registrational Phase 3 trial for AlloNK® and generate sufficient trial and pooled safety data to support a BLA submission, and Artiva’s expectations on timing and FDA alignment with such strategy; Artiva’s expectations on the timing to initiate and report data for the Phase 3 trial; Artiva’s expectations with respect to ACR50 responses in the Phase 3 trial for both

AlloNK® and the control arm; estimates regarding the size of patient populations and response rates to existing therapies; the potential market opportunity for AlloNK®; Artiva’s future results of operations and financial position, including cash runway; and Artiva’s presentation plans. These forward-looking statements are based on the beliefs of the management of Artiva as well as assumptions made by and information currently available to Artiva. Such statements reflect the current views of Artiva with respect to future events and are subject to known and unknown risks and uncertainties,... (truncated)a’s ability to obtain adequate financing to fund its planned clinical trials and other expenses; risks that future clinical trial results may not be consistent with interim, initial, preliminary, or topline results or results from prior preclinical studies or clinical trials; the risk that Artiva’s registrational strategy is based in part on its views following its recent meeting with the

FDA and later feedback from the FDA may be inconsistent with such meeting or its views from such meeting, including the risk that the official FDA minutes which Artiva expects to receive in the coming weeks may include interpretations, requests for additional data, or conclusions that differ from Artiva’s understanding of prior discussions; the risk that differences exist between trial designs, patient characteristics and other factors for the Artiva-sponsored Phase 2a basket trial and an investigator-initiated basket trial, and caution should be exercised in drawing any conclusions from such data across separate trials as such pooling and comparative data is inherently limited and such data may not be directly comparable; and risks related to the legal and regulatory framework for the industry. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause

Artiva’s actual results to differ from current expectations are discussed in Artiva’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in Artiva’s

Quarterly Report on Form

10-Q for the quarter ended March 31, 2026. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, Artiva undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Artiva Biotherapeutics, Inc.

Condensed Balance Sheets

(Unaudited)

(in thousands)

Artiva Biotherapeutics, Inc.

Condensed Statements of Operations and Comprehensive Loss

(Unaudited)

(in thousands, except share and per share data)

Contacts

Investors

Noopur Batsha Liffick, MPH

NBL LifeSci Advisory LLC ir@artivabio.com

Media

Jessica Yingling, Ph.D.

Little Dog Communications

Inc. jessica@litldog.com

Source: Artiva

Biotherapeutics, Inc.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Artiva Biotherapeutics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.